Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu"
Abstract
Department of gastric surgery, Department of Melanoma, Oncological Institute from Moldova, First Department of Surgery “N. Anestiadi” and Laboratory of Hepato-pancreato-biliary Surgery, SUMPh "N.Testemitanu", Institute of Emergency Medicine, Department of oncology, SUMPh "N.Testemitanu", Chișinău, Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltareIntroduction: Gastrointestinal stromal tumors (GIST) represent
0.1-3% of all mesenchymal neoplasms of the gastrointestinal
tract and giant gastric (GG) GIST are rare. Purpose: Study of
clinical, histopathological and immunohistochemical features
and treatment results of GG GIST. Material and methods: 92
cases with GG GIST (c-kit(CD117)(+) treated between 2007-2019.
Conclusions: GG GIST are rare, but possess a higher risk of
progression. Complex treatment is the best curative option.
Keywords: giant GIST, complex treatment, high risk.
Results: A review of the database of 92 gastric GIST patients
with positivity to the specific marker c-KIT(CD117) was
performed. The study group consisted of 14 patients with GIST of
the stomach. M:F=1.8:1. Mean age-59.78±2.35 years.
Surgical options: excision of gastric tumor-2 (14,3%), gastric
wedge resection - 7 (50%), partial gastrectomy - 5 (35,7%). The
mean maximum size of tumors was 23.69±0.81 cm.
Immunohistochemical phenotype: CD117(+)-14(100%), CD34(+)
-12(85.7%), desmin(+)-3(21.4%), vimentin(+)-10(71.4%). Mean
number of mitoses–24.36±6.3. Tumors with high mitotic count
were registered more frequent than with low mitotic count –
11(78.6%) vs. 3(21.4%) (p<0.05). Metastases at first presentation
– 28.6%(n=4) cases. Complex treatment – surgery and imatinib
mesylate–in 14(100%) patients.
Conclusions: GG GIST are rare, but possess a higher risk of
progression. Complex treatment is the best curative option